Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Company Overview
Gossamer Bio, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, acquisition, development, and commercialization of novel therapeutic candidates. The company is strategically positioned in the fields of immunology, inflammation, and oncology, utilizing an asset-rich in-licensing model that leverages the deep experience of its founding team. This approach focuses on targeting high unmet needs among patient populations with conditions that are complex and challenging to manage, ensuring that Gossamer Bio remains relevant in addressing critical healthcare issues.
Core Business Areas
The company’s operations are centered on identifying and advancing therapeutic candidates that address key disease mechanisms such as cellular overgrowth, fibrosis, and dysregulated vascular remodeling. By focusing on immunology, inflammation, and oncology, Gossamer Bio develops treatments aimed at conditions including pulmonary arterial hypertension, inflammatory bowel diseases like ulcerative colitis and Crohn’s disease, specific oncology indications, and moderate-to-severe respiratory conditions such as eosinophilic asthma. Its expert research and development team capitalizes on proven methodologies in drug discovery, ensuring that each candidate is backed by comprehensive preclinical and clinical evaluation.
Gossamer Bio reported a net loss of $234 million for the full year 2021, or $3.13 per share, an improvement over 2020's loss. Cash and equivalents totaled $325 million, sufficient to fund operations into late 2023. Two Phase 2 trials, GB004 for ulcerative colitis and Seralutinib for pulmonary arterial hypertension, are ongoing, with results expected in 2022. R&D expenses rose to $170.3 million for 2021, driven by clinical trials. The company plans a conference call for March 3 to discuss its financial results and updates.
Gossamer Bio, Inc. (GOSS) will announce its fourth quarter and full-year 2021 financial results on March 3, 2022. A live conference call and webcast will follow at 4:30 p.m. ET that same day, where management will discuss the financial results and provide a corporate update. Investors can access the live webcast at this link, with a replay available for 30 days on the company’s website. Gossamer Bio focuses on developing therapeutics for immunology, inflammation, and oncology.
Onxeo S.A. has appointed Bryan Giraudo, COO & CFO of Gossamer Bio, as an independent member of its Board of Directors, replacing Thomas Hofstaetter. Giraudo brings extensive financial expertise and a strong network in the U.S. life sciences sector. His appointment aims to strengthen Onxeo's international focus, especially in developing its innovative oncology drug, AsiDNA™, which targets DNA Damage Response (DDR). Chairwoman Shefali Agarwal and CEO Judith Greciet lauded his financial acumen and strategic insights.
Gossamer Bio reported its third quarter 2021 results, highlighting significant cash reserves of $366 million as of September 30, 2021. The company is advancing its clinical programs including Seralutinib, with phase 2 topline results now expected in H2 2022 due to COVID-19 delays. Additionally, the SHIFT-UC study has completed enrollment, with initial results anticipated in Q2 2022. R&D expenses rose to $43.2 million, while the net loss for the quarter was $60.2 million, maintaining the same per-share loss as in 2020.
Gossamer Bio, Inc. (NASDAQ: GOSS), a clinical-stage biopharmaceutical company, will report its third quarter 2021 financial results on November 8, 2021. The management team will hold a live conference call at 4:15 p.m. ET to discuss financial results and provide a corporate update. Interested parties can join via domestic and international dial-in numbers or through a live webcast. A replay will be available for 30 days on Gossamer's website, ensuring accessibility for investors and stakeholders.
Gossamer Bio (NASDAQ: GOSS) announced two new CNS-penetrant Bruton’s tyrosine kinase (BTK) inhibitors, GB5121 and GB7208, aimed at treating central nervous system malignancies and diseases. The first-in-human trial for GB5121 is set for Q4 2021, targeting relapsed/refractory primary CNS lymphoma. GB7208 is progressing towards clinical trials with promising preclinical outcomes. Both candidates exhibit superior CNS penetration and selectivity compared to existing treatments, addressing unmet needs in oncology and neurology.
Gossamer Bio, Inc. (NASDAQ: GOSS) has scheduled a conference call and webcast for investors on
Investors can access the live webcast on Gossamer's website or dial in using the provided numbers. A replay will be available for 30 days.
Gossamer Bio, Inc. (NASDAQ: GOSS) has appointed Bryan Giraudo as Chief Operating Officer, maintaining his role as Chief Financial Officer. He joined Gossamer in May 2018 and has significantly contributed to the company's financial and organizational strength. Giraudo's promotion reflects his expanding leadership role. Before joining Gossamer, he was a Senior Managing Director at SVB Leerink and a Managing Director at Merrill Lynch's Global Healthcare Investment Banking Group. Gossamer Bio focuses on therapeutics in immunology, inflammation, and oncology.
Gossamer Bio, Inc. (Nasdaq: GOSS) reported its Q2 2021 financial results, highlighting a net loss of $59.8 million, or $0.80 per share, an improvement from a net loss of $66.9 million, or $1.00 per share in Q2 2020. As of June 30, 2021, cash, cash equivalents, and marketable securities totaled $405.9 million, projected to fund operations through H2 2023. Key clinical updates include ongoing Phase 2 studies for seralutinib and GB004, with safety data showing promise in PAH treatment. However, Gossamer will discontinue further development of GB1275.
Gossamer Bio (Nasdaq: GOSS) announced it will report its Q2 2021 financial results on August 9, 2021. The live conference call will take place at 4:30 p.m. ET, where management will discuss the results and provide a corporate update. Investors can join the call via domestic at (833) 646-0603 or international at (929) 517-9782. A replay will be available for 30 days on their website, www.gossamerbio.com. Gossamer is focused on developing therapeutics in immunology, inflammation, and oncology.
FAQ
What is the current stock price of Gossamer Bio (GOSS)?
What is the market cap of Gossamer Bio (GOSS)?
What is Gossamer Bio's core business focus?
How does Gossamer Bio generate revenue?
What therapeutic areas does the company target?
How does the company differentiate itself from competitors?
What is the significance of focusing on high unmet needs?
What role does the company’s clinical-stage status play in its operations?
